CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019	[1]
Current assets:
Cash and cash equivalents	$ 351,981	$ 278,096
Short-term marketable securities	31,970	72,749
Related party receivables from collaborative arrangements	82,134	79,427
Prepaid expenses and other current assets	822	962
Total current assets	466,907	431,234
Property and equipment, net	42	33
Equity investments	46,915	0
Capitalized fees paid to a related party, net	135,620	139,076
Deferred tax assets, net	138,239	154,171
Other assets	288	312
Total assets	788,011	724,826
Current liabilities:
Accounts payable	122	10
Accrued personnel-related expenses	274	647
Accrued interest payable	1,668	4,152
Other accrued liabilities	734	562
Total current liabilities	2,798	5,371
Long-term debt, net of discount and issuance costs	379,152	377,120
Other long-term liabilities	192	219
Commitments and contingencies (Note 7)
Stockholders' equity:
Preferred stock: $0.01 par value, 230 shares authorized, no shares issued and outstanding	0	0
Common stock: $0.01 par value, 200,000 shares authorized, 101,320 and 101,288 issued and outstanding as of March 31, 2020 and December 31, 2019, respectively	1,013	1,013
Additional paid-in capital	1,259,464	1,258,859
Accumulated other comprehensive income	33	27
Accumulated deficit	(880,967)	(946,404)
Total Innoviva stockholders' equity	379,543	313,495
Noncontrolling interest	26,326	28,621
Total stockholders' equity	405,869	342,116
Total liabilities and stockholders' equity	$ 788,011	$ 724,826

[1] Consolidated balance sheet as of December 31, 2019 has been derived from audited consolidated financial statements.